Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet
Cecília Monteiro(Kaiser Permanente South San Francisco Medical Center), William Alvin McElveen, Kristin R. Wildsmith(Eisai (United States)), Michael Dolton, Veronica G. Anania, Pierre Krolak‐Salmon, Miquel Baquero Toledo, Marc Agronin, Ira Goodman, Lamberto Landete Pascual, Jerzy Krupiński(University Hospital Mútua de Terrassa), Daniel Abramzon(Kaiser Permanente South San Francisco Medical Center), Jennifer Arnold, Flávia Brunstein, Edmond Teng, Ashwini Bobbala, William Justiz, Ryan Ceniceros(Kaiser Permanente South San Francisco Medical Center), Scott Losk, Jan Ilkowski(Poznan University of Medical Sciences), Rafael Blesa González, Gad A. Marshall, Concetta Forchetti, Maciej Czarnecki, Keith R. Edwards, Jacek Dobryniewski, Thomas Arnold, Vidya Ramakrishnan, Mark Brody, Orlando Maldonado-Robles, Sandra Sanabria Bohórquez, Wendy Bond, Roxana Hanta Cezara, Balázs István Tóth(Kaiser Permanente South San Francisco Medical Center), Walter Martínez, Julie Lee(Kaiser Permanente South San Francisco Medical Center), Seema Datta(Kaiser Permanente South San Francisco Medical Center), Puja Aggarwal, Stephen Schauer(Unknown), Richard Levy, Mathieu Ceccaldi, Bruno Dubois(Portland State University), A. Lleó Bisa, A. Thomas, Peter McAllister(New England Institute for Neurology and Headache), Antonio del Olmo Rodríguez
Cited by 104
Related Papers
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
|Neurology|2016|1.9k
Defeating Alzheimer's disease and other dementias: a priority for European science and society
|The Lancet Neurology|2016|1.7k